Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bioequivalence of Two Different Capsule Types of Dabigatran

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate

First Posted Date: 2011-02-07

Last Posted Date: 2014-05-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 180

Registration Number: NCT01290757

Locations: 🇩🇪
1160.117.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: BI 10773
Drug: Sitagliptin 100mg

First Posted Date: 2011-02-04

Last Posted Date: 2014-07-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2705

Registration Number: NCT01289990

Locations: 🇨🇦
1245.31.20018 Boehringer Ingelheim Investigational Site, Victoria, British Columbia, Canada
🇮🇪
1245.31.35305 Boehringer Ingelheim Investigational Site, Co. Galway, Ireland
🇺🇸
1245.31.10034 Boehringer Ingelheim Investigational Site, Rochester, New York, United States

and more 240 locations

Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 135585

First Posted Date: 2011-01-31

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT01286571

Locations: 🇩🇪
1283.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: 5 mg amlodipine
Drug: 40 mg telmisartan
Drug: 80 mg telmisartan

First Posted Date: 2011-01-31

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 225

Registration Number: NCT01286558

Locations: 🇯🇵
1235.37.08 Boehringer Ingelheim Investigational Site, Itoshima, Fukuoka, Japan
🇯🇵
1235.37.01 Boehringer Ingelheim Investigational Site, Chuo-ku,Tokyo, Japan
🇯🇵
1235.37.05 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan

and more 5 locations

Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: Ramipril

First Posted Date: 2011-01-27

Last Posted Date: 2014-07-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 23

Registration Number: NCT01284621

Locations: 🇩🇪
1245.45.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo to BI 135585
Drug: BI 135585

First Posted Date: 2011-01-25

Last Posted Date: 2014-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT01282970

Locations: 🇩🇪
1283.2.1 Boehringer Ingelheim Investigational Site, Neuss, Germany

Telmisartan and Amlodipine Versus Monocomponent Tablets

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan/Amlodipine Combination Tablet
Drug: Amlodipine Monocomponent

First Posted Date: 2011-01-19

Last Posted Date: 2014-03-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT01278797

Locations: 🇨🇦
1235.41.0001 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada

Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: tiotropium high dose
Drug: placebo
Drug: tiotropium low dose

First Posted Date: 2011-01-17

Last Posted Date: 2014-10-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 392

Registration Number: NCT01277523

Locations: 🇺🇸
205.456.01003 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇵🇹
205.456.35101 Boehringer Ingelheim Investigational Site, Lisboa, Portugal
🇵🇹
205.456.35103 Boehringer Ingelheim Investigational Site, Porto, Portugal

and more 66 locations

Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.

Phase 1

Withdrawn

Conditions: HIV Infections
Healthy

Interventions: Drug: BI 224436
Drug: Placebo

First Posted Date: 2011-01-14

Last Posted Date: 2012-02-09

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT01276990

Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 10773
Drug: hydrochlorothiazide
Drug: torasemide

First Posted Date: 2011-01-13

Last Posted Date: 2014-09-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 23

Registration Number: NCT01276288

Locations: 🇩🇪
1245.42.1 Boehringer Ingelheim Investigational Site, Neuss, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy